Evaluations of buparvaquone as a treatment for equine babesiosis (Babesia equi).

This study examines the efficiency of buparvaquone as a treatment for equine babesiosis, a parasitic disease affecting horses. The results indicate that buparvaquone, when administered at specific doses, was able to eliminate the parasitic infection in some, but not all, cases.

Study Purpose and Structure

• The research aimed to investigate the effectiveness of a drug called buparvaquone in treating equine babesiosis, a specific parasitic infection in horses, especially those of European origin.
• The drug was tested both on carrier horses with an existing infection, and on experimental ponies specifically infected for the study. The denomination ‘splectomized’ is used to indicate ponies who had their spleen removed, a condition that exacerbates the effects of the parasitic infection.

Methodology and Dosages

• Buparvaquone was first administered in doses of 2.5 mg/kg of body weight via intramuscular (IM) injections. The injections were administered four times, spaced by an interval of 96 hours.
• The researchers also experimented with different doses of the medication, ranging from 2.5 mg/kg to 5 mg/kg, via intramuscular injections. In another setting, the doses varied from 4 to 6 mg/kg, given either intravenously (IV) or intramuscularly.

Findings and Outcome

• The buparvaquone treatment was able to eliminate Babesia equi — the bacterium causing equine babesiosis — from 1 horsе, but this result could not be replicated in other horses or ponies using the same or different dosage.
• However, the drug was found to be effectual in treating 4 out of the 5 cases of acute Babesia equi infection presented in splectomized ponies when administered at rates of 4 to 6 mg/kg, either intravenously or intramuscularly. It is important to note that these treated ponies became carriers of the infection.

This investigation provides important insights into the use of buparvaquone as a potential treatment method for equine babesiosis. However, the variability in results depending on dosage and the subsequent carrier status suggests the need for further studies to optimize the use of the drug.